Table 1 Patients’ characteristics
Bounce (-) | Bounce (+) | p value | |
|---|---|---|---|
(n = 150) | (n = 50) | ||
Age (year) | |||
mean, median (range) | 69.2, 70.0 (55-80) | 67.4, 68.5 (51-79) | 0.132§ |
PSA at diagnosis (ng/mL) | |||
mean, median (range) | 9.1, 7.8 (3.1-32.1) | 7.8, 6.7 (3.7-16.7) | 0.029§ |
10 or less | 106 | 41 | |
10-20 | 37 | 9 | |
greater than 20 | 7 | 0 | 0.156* |
biopsy Gleason score | |||
6 or less | 91 | 37 | |
7 | 53 | 11 | |
8-10 | 6 | 2 | 0.210* |
clinical T stage | |||
T1c | 88 | 32 | |
T2a | 50 | 15 | |
T2b | 7 | 2 | |
T2c | 5 | 1 | 0.904* |
neo-Adjuvant/ Adjuvant | |||
none | 102 | 35 | |
neo-Ad (+) | 40 | 15 | |
Ad (+) | 4 | 0 | |
neo-Ad (+), Ad (+) | 4 | 0 | 0.417* |
Combined EBRT | |||
yes | 49 | 9 | |
no | 101 | 41 | 0.050* |
biochemical recurrence | |||
yes | 10 | 0 | |
no | 140 | 50 | 0.069* |
Number of PSA measurement | |||
mean, median (range) | 8.5, 8.0 (5-15) | 10.3, 10.5 (6-14) | < 0.001§ |
Follow-up period (month) | |||
mean, median (range) | 36.7, 36.0 (18-64) | 46.0, 47.0 (20-65) | < 0.001§ |